Compare iShares Self-Driving EV and Tech (IDRV) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Organon & Co. Common Stock — how do they compare? iShares Self-Driving EV and Tech trades at $32 (market cap $258.76M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 14× iShares Self-Driving EV and Tech's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 75 Days and Organon & Co. Common Stock for 0 Days on average.
| IDRV | OGN | |
|---|---|---|
Market Cap | $258.76M | $3.62B |
Volume | 39,075 | 2,892,999 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $13.81 |
52-Week Low | $32.18 | $5.70 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $32.78, up 0.43% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from lukewarm US electric vehicle adoption despite global EV sales growth. Key support sits at $32 with resistance at $33-34 levels, while oscillators remain neutral suggesting potential consolidation.
The EV sector faces mixed signals with regulatory uncertainty and oil price volatility creating near-term challenges. Long-term prospects remain tied to global EV adoption trends, particularly in China and Europe where growth continues. Investors should weigh regulatory risks against the sector's structural growth trajectory.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
